Jazz Pharmaceuticals PLC
JAZZHealthcare|Biotechnology|Ireland
$243.79
-3.09 (-1.25%)
DCF (FCF)
$213.42
Earnings Power
$74.91
Clinical Trials (288)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05044819 Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | Lennox Gastaut Syndrome, Dravet Syndrome | P4 | Active | 154 | Open-label | Cannabidiol |
| NCT05091567 A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | Small-Cell Lung Cancer | P3 | Active | 660 | RCT, Open-label | Atezolizumab, Lurbinectedin, Carboplatin, Etoposide |
| NCT03897127 Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | Acute Myeloid Leukemia | P3 | Active | 882 | RCT, Open-label | Cytarabine, Daunorubicin, CPX-351 |
| NCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | Gastric Neoplasms, Gastroesophageal Adenocarcinoma | P3 | Active | 920 | RCT, Open-label | Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil |
| NCT05580562 ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | H3 K27M, Glioma | P3 | Recruiting | 510 | RCT, Double-blind | Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo |
| NCT05476939 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | P3 | Recruiting | 433 | RCT, Open-label | Everolimus, ONC201 |
| NCT06282575 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Biliary Tract Cancer | P3 | Recruiting | 286 | RCT, Open-label | Zanidatamab, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab |
| NCT04217278 A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome | P2P3 | Active | 333 | RCT, Open-label | Vyxeos, Fludarabine, Busulphan, Thiotepa, Cytarabine |
| NCT06435429 A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Metastatic HER2-positive Breast Cancer | P3 | Recruiting | 550 | RCT, Open-label | Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine |
| NCT05629702 ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids | Glioblastoma, Brain Tumor | P2 | Recruiting | 120 | RCT, Double-blind | Nabiximols, Temozolomide, Nabiximols-matched placebo |
| NCT03825796 CPX-351 Plus Enasidenib for Relapsed AML | Recurrent Acute Myeloid Leukemia | P2 | Active | 2 | Open-label | Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine |
| NCT07102381 A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | HER2-positive Breast Cancer, Breast Cancer | P2 | Recruiting | 125 | RCT, Open-label | Zanidatamab, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab |
| NCT04652115 Defibrotide for the Treatment of Severe COVID-19 | Covid19 | P2 | Recruiting | 42 | Open-label | Defibrotide |
| NCT03202303 Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) | Autism Spectrum Disorder | P2 | Recruiting | 100 | RCT, Double-blind | Cannabidivarin, Matched Placebo |
| NCT06043427 Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | Gastroesophageal Adenocarcinoma | P2 | Recruiting | 168 | RCT, Open-label | Paclitaxel, Ramucirumab, Zanidatamab |
| NCT07282587 Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Advanced Pheochromocytoma and Paraganglioma, PCPG | P2 | Recruiting | 90 | RCT, Open-label | ONC206, ONC206: Dose 1, ONC206: Dose 2 |
| NCT05734066 Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma | P1P2 | Recruiting | 60 | Open-label | Lurbinectedin |
| NCT05099666 Lurbinectedin + Doxorubicin In Leiomyosarcoma | Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | P1P2 | Active | 62 | RCT, Open-label | Lurbinectedin, Doxorubicin |
| NCT04231851 CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia | Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | P2 | Active | 30 | Open-label | Glasdegib, CPX-351 |
| NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer, Gastric Cancer | P2 | Recruiting | 200 | Open-label | Zanidatamab |
| NCT06738368 Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | P2 | Recruiting | 30 | Open-label | Asparaginase Erwinia chrysanthemi, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Prednisone, Rituximab, Vincristine |
| NCT04269213 CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | P2 | Active | 21 | Open-label | Liposome-encapsulated Daunorubicin-Cytarabine |
| NCT05656248 Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms | Myeloid Neoplasm | P2 | Active | 25 | Open-label | CPX-351, MHA |
| NCT07153055 Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer | Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | P1P2 | Recruiting | 16 | Open-label | Lurbinectedin, Osimertinib |
| NCT07176312 Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients | Gastroesophageal Adenocarcinoma, First Line Therapy | P2 | Recruiting | 80 | Open-label | Zanidatamab, Pembrolizumab, mFOLFOX |
| NCT04990102 Phase IB/II of CPX-351 for Relapse Prevention in AML | Acute Myeloid Leukemia (AML) in Remission | P1P2 | Recruiting | 24 | Open-label | CPX-351 |
| NCT05260528 CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics | Acute Myeloid Leukemia | P2 | Recruiting | 248 | RCT, Open-label | Cytarabine and Idarubicin, CPX-315 |
| NCT07192068 Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. | Non-Small Cell Lung Cancer, Sarcoma | P2 | Recruiting | 105 | Open-label | Zanidatamab |
| NCT05918640 Lurbinectedin in FET-Fused Tumors | Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | P1P2 | Recruiting | 63 | Open-label | Lurbinectedin |
| NCT05009992 Combination Therapy for the Treatment of Diffuse Midline Gliomas | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | P2 | Recruiting | 360 | RCT, Open-label | ONC201, Paxalisib, DNX-2401 |
| NCT07278505 Study of Cannabidiol and Neuroimaging on Stress | Early Life Adversity, Trauma | P1P2 | Recruiting | 160 | RCT, Double-blind | Cannabidiol, Placebo |
| NCT05636111 Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | Ovarian Cancer | P1 | Recruiting | 34 | Open-label | Paclitaxel, Bevacizumab, Lurbinectedin |
| NCT05542407 ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Endometrial Cancer, Metastasis | P1 | Recruiting | 58 | Open-label | Atezolizumab, ONC201 |
| NCT07156435 Vyxeos® With Clofarabine for Pediatric AML | Relapsed Pediatric AML, Refractory Pediatric AML | P1 | Recruiting | 25 | Open-label | Vyxeos 44 MG / 100 MG Liposome Injection, Clofarabine |
| NCT06108050 JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Advanced Solid Tumor, Metastatic Solid Tumor | P1 | Recruiting | 177 | Open-label | JZP898, Pembrolizumab |
| NCT05558124 CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | Acute Myeloid Leukemia | P1 | Recruiting | 18 | Open-label | Vyxeos, Gemtuzumab Ozogamicin |
| NCT03572764 CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome | Myelodysplastic Syndromes | P1 | Active | 20 | Open-label | CPX-351 |
| NCT07377539 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants | Healthy Participants | P1 | Recruiting | 86 | RCT, Double-blind | JZP047 |
| NCT07233239 A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | Focal Seizures | P1 | Recruiting | 100 | Open-label | CBD-OS |
| NCT05557045 A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Advanced Cancer, Metastatic Cancer | P1 | Recruiting | 332 | Open-label | JZP815 |
| NCT04732065 ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors | Diffuse Midline Glioma (DMG), Glioblastoma | P1 | Recruiting | 208 | Open-label | ONC206 |
| NCT04541082 Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Central Nervous System Neoplasms, Glioblastoma | P1 | Recruiting | 102 | Open-label | ONC206 |
| NCT05244239 Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | P1 | Recruiting | 22 | Open-label | Lurbinectedin |
| NCT05024552 Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | Acute Myeloid Leukemia With FLT3/ITD Mutation | P1 | Recruiting | 22 | Open-label | Gilteritinib, Vyxeos |
| NCT06113237 Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy | Maternal Complications, Pregnancy Complication | Recruiting | 50 | — | Epidiolex | |
| NCT05485831 Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY | Lennox Gastaut Syndrome, Dravet Syndrome | Active | 111 | — | Epidiolex 100 mg/mL Oral Solution | |
| NCT05850676 Disentangling the Role of Depression in Hypersomnia | Hypersomnia | Recruiting | 45 | — | — | |
| NCT04899947 Child and Adolescent Registry for Participants With Narcolepsy | Narcolepsy | Recruiting | 500 | — | — | |
| NCT03865589 Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome | Bone Marrow Transplant Complications, Sinusoidal Obstruction Syndrome | N/A | Active | 250 | Open-label | — |
| NCT05772429 Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting | Seizures | Active | 158 | — | Epidiolex | |
| NCT04602936 Solriamfetol in Binge Eating Disorder | Binge Eating Disorder | P4 | Unknown | 64 | RCT, Double-blind | Solriamfetol, Placebo |
| NCT00506974 Enhancing Slow Wave Sleep With Sodium Oxybate | Sleep | P4 | Completed | 60 | RCT, Double-blind | sodium oxybate |
| NCT00086281 Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients | Obstructive Sleep Apnea Syndrome | P4 | Completed | 60 | RCT, Double-blind | Xyrem (X), Zolpidem (Z), Modafinil (M), Placebo (P) |
| NCT00498485 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome | Chronic Fatigue Syndrome | P4 | Terminated | 17 | RCT, Double-blind | Placebo, Sodium Oxybate |
| NCT04133480 Investigation of Cognitive Outcomes With Cannabidiol Oral Solution | Lennox-Gastaut Syndrome | P4 | Withdrawn | — | Open-label | GWP42003-P |
| NCT05864846 A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | P4 | Completed | 79 | Open-label | Cannabidiol Oral Solution [Epidiolex] |
| NCT01964547 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients | Multiple Sclerosis, Spasticity | P4 | Completed | 121 | RCT, Double-blind | Sativex, Placebo |
| NCT00670696 A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel | Healthy, Anesthesia | P4 | Withdrawn | — | RCT, Single-blind | Rapydan, tetracaine gel |
| NCT05875974 A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy | Idiopathic Hypersomnia, Narcolepsy | P4 | Completed | 207 | Open-label | JZP258 (XYWAV) |
| NCT05869773 A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy | Narcolepsy | P4 | Completed | 155 | Open-label | JZP258 |
| NCT04899050 Epidiolex in Typical Absence Seizures | Study the Efficacy of Epidiolex for Typical Absence Seizures | P4 | Completed | 14 | Open-label | Cannabidiol (Epidiolex) |
| NCT06924827 A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | P4 | Not Yet Recruiting | 25 | Open-label | Epidiolex 100 mg/mL Oral Solution |
| NCT04006925 Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate | REM Sleep Behavior Disorder, Parkinson Disease | P4 | Completed | 24 | RCT, Double-blind | Sodium Oxybate |
| NCT04794491 An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy | Narcolepsy | P4 | Completed | 62 | Open-label | JZP-258 |
| NCT01599234 A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis | Multiple Sclerosis | P3 | Completed | 337 | RCT, Double-blind | Sativex, Placebo |
| NCT02221869 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy | Narcolepsy With Cataplexy | P3 | Completed | 106 | RCT, Double-blind | Xyrem |
| NCT04203498 Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis | Multiple Sclerosis (MS) | P3 | Terminated | 139 | RCT, Double-blind | Nabiximols, Placebo |
| NCT02087306 Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection | Adenovirus Infection | P3 | Completed | 201 | Open-label | Brincidofovir |
| NCT00106860 A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder | Anxiety Disorder | P3 | Completed | 158 | Open-label | a benzodiazepine drug |
| NCT00710424 A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy | Pain, Diabetic Neuropathy | P3 | Completed | 297 | RCT, Double-blind | Sativex, Placebo |
| NCT01696084 Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia | High Risk Acute Myeloid Leukemia | P3 | Completed | 309 | RCT, Open-label | CPX-351, 7+3 (cytarabine and daunorubicin) |
| NCT00097708 Experimental Medication For the Treatment of Generalized Anxiety Disorder | Anxiety Disorder | P3 | Completed | 511 | RCT, Double-blind | experimental anti-anxiety drug |
| NCT01606137 A Study of the Long-term Safety of Sativex Use | Multiple Sclerosis, Spasticity | P3 | Completed | 507 | Open-label | GW-1000-02 |
| NCT04592159 Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder | Post-Traumatic Stress Disorder | P2P3 | Withdrawn | — | RCT, Double-blind | Nabiximols, Placebo |
| NCT01898520 A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years | Cerebral Palsy | P3 | Completed | 72 | RCT, Double-blind | Sativex, Placebo |
| NCT00132873 Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy | Narcolepsy | P3 | Completed | 59 | Open-label | Xyrem (sodium oxybate) oral solution |
| NCT00681538 A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS) | Spasticity, Multiple Sclerosis | P3 | Completed | 572 | RCT, Double-blind | Sativex®, Placebo |
| NCT04252586 A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | Rett Syndrome, RTT | P3 | Terminated | 21 | Open-label | GWP42003-P |
| NCT01265810 Caphosol in Oral Mucositis Due to Targeted Therapy | Oral Complaints, Renal Cell Carcinoma | P3 | Completed | 64 | RCT, Double-blind | — |
| NCT01606176 A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin | Pain, Multiple Sclerosis | P3 | Completed | 70 | RCT, Double-blind | GW-1000-02, Placebo |
| NCT00713323 A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain. | Pain, Peripheral Neuropathy | P3 | Completed | 380 | Open-label | Sativex® |
| NCT02954887 Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) | Infantile Spasms | P3 | Completed | 9 | Open-label | GWP42003-P |
| NCT01361607 Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer | Pain, Advanced Cancer | P3 | Completed | 399 | RCT, Double-blind | Nabiximols, Placebo (GA-0034) |
| NCT00628498 Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study | Hepatic Veno-Occlusive Disease | P3 | Completed | 1,206 | Open-label | Defibrotide, Defibrotide |
| NCT02224560 Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | Epilepsy, Lennox Gastaut Syndrome | P3 | Completed | 225 | RCT, Double-blind | GWP42003-P, Placebo control |
| NCT07625280 A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH | Narcolepsy, Idiopathic Hypersomnia | P3 | Not Yet Recruiting | 108 | RCT, Double-blind | Xywav |
| NCT02851407 Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients | Veno-occlusive Disease | P3 | Completed | 372 | RCT, Open-label | Defibrotide |
| NCT02348593 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" | Narcolepsy | P3 | Completed | 239 | RCT, Double-blind | JZP-110, Placebo oral tablet |
| NCT02544763 A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) | Tuberous Sclerosis Complex, Seizures | P3 | Completed | 224 | RCT, Double-blind | GWP42003-P, Placebo |
| NCT02953548 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) | Infantile Spasms | P3 | Completed | 9 | Open-label | GWP42003-P |
| NCT00678795 A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis | Detrusor Overactivity, Multiple Sclerosis | P3 | Completed | 135 | RCT, Double-blind | Sativex®, Placebo |
| NCT00675948 Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain | Pain, Cancer | P3 | Completed | 43 | Open-label | Sativex, GW-2000-02 |
| NCT00711880 A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia. | Pain, Peripheral Neuropathy | P3 | Completed | 125 | RCT, Double-blind | Sativex®, Placebo |
| NCT00713817 A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain | Pain, Peripheral Neuropathy | P3 | Completed | 19 | RCT, Double-blind | Sativex®, Placebo |
| NCT01610713 An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis | Multiple Sclerosis | P3 | Completed | 154 | Open-label | GW-1000-02 |
| NCT05288283 Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures | Seizures Associated With EMAS | P3 | Terminated | 3 | RCT, Double-blind | GWP42003-P, Placebo |
| NCT02439970 A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease | Cytomegalovirus Disease | P3 | Terminated | 5 | RCT, Double-blind | Brincidofovir, Valganciclovir |
| NCT00371137 A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia | Fibromyalgia | P3 | Completed | 548 | RCT, Double-blind | Xyrem®, Placebo |
| NCT00674609 A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy | Palliative Care, Pain | P3 | Completed | 177 | RCT, Double-blind | Placebo, Sativex®, THC Alone |
| NCT04571645 Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia | Acute Myeloid Leukemia | P3 | Terminated | 9 | RCT, Double-blind | Dociparstat |
| NCT04145531 An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia | P2P3 | Completed | 229 | Open-label | IM JZP-458, IV JZP-458 |
| NCT00423813 A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia. | Fibromyalgia | P3 | Completed | 573 | RCT, Double-blind | placebo, Xyrem® |
| NCT00514995 Sodium Oxybate in the Treatment of Binge Eating Disorder | Binge Eating Disorder | P2P3 | Completed | 15 | Open-label | Sodium Oxybate |
| NCT02348619 "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" | Obstructive Sleep Apnea | P3 | Completed | 174 | RCT, Double-blind | JZP-110 |
| NCT00272948 Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide | Hepatic Veno-Occlusive Disease | P2P3 | Completed | 360 | RCT, Open-label | Defibrotide, Defibrotide, Defibrotide |
| NCT00358501 Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients | Severe Hepatic Veno-Occlusive Disease | P3 | Completed | 134 | Open-label | Defibrotide |
| NCT01610687 A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis | Multiple Sclerosis, Spasticity | P3 | Completed | 137 | Open-label | GW-1000-02 |
| NCT01337089 Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain | Pain, Advanced Cancer | P3 | Completed | 660 | Open-label | Nabiximols |
| NCT02283281 Anesthetic Premedication With a Cannabis Extract (Cannapremed) | Pain, Postoperative, Postoperative Nausea and Vomiting | P2P3 | Unknown | 200 | RCT, Double-blind | Tetrahydrocannabinol, Dummy oromucosal |
| NCT04984278 Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis | Spasticity With Multiple Sclerosis | P3 | Terminated | 56 | RCT, Double-blind | Nabiximols, Placebo |
| NCT03533114 A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension | Idiopathic Hypersomnia | P3 | Completed | 154 | RCT, Double-blind | JZP-258, Placebo Oral Solution |
| NCT01606202 A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury | Pain | P3 | Completed | 116 | RCT, Double-blind | GW-1000-02, Placebo |
| NCT01143181 Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses | Double-stranded DNA Virus | P3 | Completed | 210 | Open-label | Brincidofovir |
| NCT01610700 An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients | Multiple Sclerosis | P3 | Completed | 160 | RCT, Double-blind | GW-1000-02, Placebo |
| NCT02348632 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" | Narcolepsy, Obstructive Sleep Apnea | P3 | Completed | 645 | Open-label | JZP-110 |
| NCT01769170 A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients | CMV | P3 | Completed | 452 | RCT, Double-blind | Brincidofovir |
| NCT07434973 Stratification and Treatment in Early Psychosis Study - PROMOTE | Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis | P3 | Not Yet Recruiting | 586 | RCT, Double-blind | Cannabidiol (CBD), Placebo |
| NCT02348606 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" | Obstructive Sleep Apnea | P3 | Completed | 476 | RCT, Double-blind | JZP-110, Placebo oral tablet |
| NCT01606189 A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain | Pain | P3 | Completed | 48 | RCT, Double-blind | GW-1000-02, GW-2000-02, Placebo |
| NCT00702468 Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis | Spasticity, Multiple Sclerosis | P3 | Completed | 36 | RCT, Double-blind | Sativex, Placebo |
| NCT04657666 Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis | Spasticity in Participants With Multiple Sclerosis | P3 | Completed | 68 | RCT, Double-blind | Nabiximols, Placebo |
| NCT00711646 A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis. | Spasticity, Multiple Sclerosis | P3 | Completed | 189 | RCT, Double-blind | Sativex®, Placebo |
| NCT00423605 Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia. | Fibromyalgia | P3 | Completed | 560 | Open-label | Xyrem® |
| NCT00066170 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy | Narcolepsy | P3 | Completed | 231 | RCT, Double-blind | Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo) |
| NCT03848832 Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | Rett Syndrome, RTT | P3 | Terminated | 29 | RCT, Double-blind | GWP42003-P, Placebo |
| NCT01424566 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer | Pain, Advanced Cancer | P3 | Completed | 406 | RCT, Double-blind | Nabiximols, Placebo (GA-0034) |
| NCT02439957 A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus | Cytomegalovirus Disease, Kidney Transplant Infection | P3 | Terminated | 6 | RCT, Double-blind | Brincidofovir, Valganciclovir |
| NCT04485104 Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures | Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome | P3 | Terminated | 3 | Open-label | GWP42003-P |
| NCT01401140 Comparing the Protective Effects of Two Cardioplegic Solutions, on Cardiac Metabolism, as Assessed Using Microdialysis | Coronary Artery Stenosis | P3 | Completed | 29 | RCT, Single-blind | St Thomas, Custodiol |
| NCT02544750 An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) | Tuberous Sclerosis Complex, Seizures | P3 | Completed | 199 | Open-label | GWP42003-P |
| NCT02091375 Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) | Epilepsy, Dravet Syndrome | P3 | Completed | 120 | RCT, Double-blind | GWP42003-P 20 mg/kg/day Dose, Placebo control |
| NCT00803023 Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia | Fibromyalgia | P3 | Completed | 129 | RCT, Single-blind | Sodium Oxybate, Sodium Oxybate & 6 Tablets, Sodium Oxybate & 8 Tablets, Sodium Oxybate Oral Solution (6 grams) |
| NCT04389840 Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | Coronavirus Disease 2019 (COVID-19), Acute Lung Injury | P2P3 | Terminated | 27 | RCT, Double-blind | Dociparstat sodium, Placebo |
| NCT02224703 GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome | Epilepsy, Dravet Syndrome | P3 | Completed | 199 | RCT, Double-blind | GWP42003-P, Placebo Control |
| NCT03030599 A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy | Narcolepsy With Cataplexy | P3 | Completed | 201 | RCT, Double-blind | JZP-258 |
| NCT02224690 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | Epilepsy, Lennox-Gastaut Syndrome | P3 | Completed | 171 | RCT, Double-blind | GWP42003-P 20 mg/kg/day Dose, Placebo |
| NCT00710554 A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia | Pain, Peripheral Neuropathy | P3 | Completed | 246 | RCT, Double-blind | Sativex, Placebo |
| NCT01604265 A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis | Multiple Sclerosis, Neuropathic Pain | P3 | Completed | 66 | RCT, Double-blind | Placebo, Sativex |
| NCT03954106 A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity | DLBCL, Neurotoxicity Syndromes | P2 | Terminated | 25 | Open-label | Defibrotide |
| NCT02053272 A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P2 | Completed | 207 | RCT, Double-blind | GWP42004, Placebo |
| NCT02332655 Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Sturge-Weber Syndrome | P1P2 | Completed | 5 | Open-label | Cannabidiol |
| NCT01426295 Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital | Hematologic Disease | P2 | Completed | 92 | RCT, Open-label | Bicarbonate de sodium |
| NCT05642442 A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease | Parkinson Disease, Tremor | P2 | Completed | 169 | RCT, Double-blind | Placebo, Suvecaltamide |
| NCT02806895 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA | Obstructive Sleep Apnea, Excessive Sleepiness | P2 | Completed | 34 | RCT, Double-blind | JZP-110, Placebo |
| NCT02238925 An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients | Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | P2 | Completed | 26 | Open-label | CPX-351 |
| NCT05178316 A Study of JZP150 in Adults With Posttraumatic Stress Disorder | Post Traumatic Stress Disorder | P2 | Completed | 282 | RCT, Double-blind | JZP150, Placebo |
| NCT03101241 A Phase 2 RCT Study of CX-8998 for Essential Tremor | Essential Tremor | P2 | Completed | 95 | RCT, Double-blind | CX-8998, Placebo |
| NCT00003966 Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation | Veno-occlusive Disease | P2 | Completed | 151 | RCT, Open-label | defibrotide |
| NCT03339297 An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) | Graft-versus-host Disease, Acute-graft-versus-host Disease | P2 | Completed | 152 | RCT, Open-label | Defibrotide, Standard of Care |
| NCT00641186 Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD) | Parkinson Disease | P2 | Completed | 30 | Open-label | sodium oxybate |
| NCT06182410 Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma | P2 | Withdrawn | — | Open-label | Defibrotide |
| NCT00594256 Sodium Oxybate in Schizophrenia With Insomnia | Schizophrenia, Insomnia Related to Schizophrenia (307.42) | P2 | Completed | 8 | Open-label | Sodium Oxybate |
| NCT01643408 A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | P2 | Completed | 30 | Open-label | asparaginase Erwinia chrysanthemi |
| NCT02607891 A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy | Epilepsy | P2 | Completed | 35 | RCT, Double-blind | GWP42003-P, Placebo |
| NCT03878199 Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | Essential Thrombocythemia, Myelofibrosis | P1P2 | Terminated | 12 | Open-label | Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib |
| NCT07459634 A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | Extensive-stage Small-cell Lung Cancer | P2 | Not Yet Recruiting | 50 | Open-label | Lurbinectedin, Durvalumab |
| NCT07533942 A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | Meningioma | P2 | Not Yet Recruiting | 30 | Open-label | JZP3507 |
| NCT02369471 A Study of GWP42006 in People With Focal Seizures - Part A | Epilepsy, Focal Seizures | P2 | Completed | 32 | RCT, Double-blind | GWP42006, Placebo |
| NCT00087555 Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia | Fibromyalgia | P2 | Completed | 195 | RCT, Double-blind | Xyrem (sodium oxybate) oral solution, Xyrem (sodium oxybate) oral solution, Placebo |
| NCT02539823 Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans | Opiate Addiction | P2 | Completed | 45 | RCT, Double-blind | CBD 400 mg, CBD 800 mg, Control (placebo) |
| NCT04268966 An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola | Ebola Virus Disease | P2 | Withdrawn | — | Open-label | Brincidofovir |
| NCT05733390 A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder | Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder | P2 | Withdrawn | — | RCT, Double-blind | JZP541 |
| NCT05122650 A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) | Essential Tremor | P2 | Completed | 420 | RCT, Double-blind | JZP385 |
| NCT02006628 A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder | Schizophrenia, Schizophrenia-related Psychotic Disorder | P2 | Completed | 88 | RCT, Double-blind | Placebo, GWP42003 |
| NCT00598078 Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor | Essential Tremor | P2 | Completed | 19 | RCT, Double-blind | Sodium Oxybate, Sodium Oxybate |
| NCT07290985 AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas | Gastroesophageal Adenocarcinoma | P2 | Not Yet Recruiting | 121 | Open-label | Tislelizumab, Leucovorin, Oxaliplatin, Fluorouracil, Zanidatamab |
| NCT05574504 Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | Metastatic Cancer, Urothelial Carcinoma | P2 | Withdrawn | — | Open-label | avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin |
| NCT01886105 Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma | Metastatic Osteosarcoma | P2 | Terminated | 4 | Open-label | Sm-EDTMP |
| NCT03485729 ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | Endometrial Cancer Recurrent | P2 | Terminated | 27 | Open-label | Dordaviprone (ONC201) |
| NCT02271347 An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease | Ebola Virus | P2 | Withdrawn | — | Open-label | CMX001 |
| NCT01681121 A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy | Narcolepsy | P2 | Completed | 93 | RCT, Double-blind | ADX-N05, Placebo |
| NCT00901732 Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer | Oral Mucositis | P1P2 | Unknown | 100 | Open-label | — |
| NCT05229588 Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations | Gastrointestinal Malignancies | P2 | Completed | 8 | Open-label | Lurbinectedin 4 MG Injection [Zepzelca] |
| NCT02038699 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Advanced Glioblastoma, Advanced Colorectal Cancer | P1P2 | Withdrawn | — | Open-label | ONC201 |
| NCT03339401 The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation | Adenovirus | P2 | Terminated | 29 | RCT, Open-label | Brincidofovir |
| NCT02873338 Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | Acute Myeloid Leukemia | P2 | Completed | 75 | RCT, Open-label | Dociparstat sodium, Idarubicin, Cytarabine |
| NCT02269579 Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | P2 | Withdrawn | — | Open-label | CPX-351 |
| NCT02150928 An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) | Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | P2 | Withdrawn | — | Open-label | Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) |
| NCT03037203 A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness | Excessive Sleepiness, Parkinson Disease | P2 | Completed | 66 | RCT, Double-blind | JZP-110 |
| NCT04224272 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer | HER2+/HR+ Breast Cancer | P2 | Completed | 51 | Open-label | ZW25 (Zanidatamab), Palbociclib, Fulvestrant |
| NCT01217112 GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes | Dyslipidemias, Diabetes Mellitus, Type 2 | P2 | Completed | 62 | RCT, Double-blind | GWP42003, GWP42003, GWP42004, Placebo |
| NCT04421456 Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment | Schizophrenia | P2 | Terminated | 95 | RCT, Double-blind | GWP42003-P, Placebo |
| NCT01461915 Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients | Metastatic Pancreatic Cancer | P2 | Terminated | 60 | RCT, Open-label | Nab paclitaxel, Gemcitabine, Dociparstat |
| NCT04447846 Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome | Sturge-Weber Syndrome | P2 | Completed | 11 | Open-label | Cannabidiol |
| NCT01485770 A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness | Narcolepsy | P2 | Completed | 33 | RCT, Double-blind | ADX-N05, Placebo |
| NCT05027139 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | HER2-expressing Cancers | P1P2 | Completed | 52 | Open-label | Zanidatamab, Evorpacept |
| NCT02718755 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies | Hematologic Malignancy | P2 | Withdrawn | — | Open-label | Fludarabine, Cytarabine, Erwinase |
| NCT03532035 Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia | Adenovirus | P2 | Withdrawn | — | RCT, Open-label | Brincidofovir, Standard of Care |
| NCT05974293 A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders | NMO Spectrum Disorder, Spasticity, Muscle | P2 | Withdrawn | — | RCT, Double-blind | Nabiximols, Placebo |
| NCT00793598 CMX001 in Post-transplant Patients With BK Virus Viruria | Viruria | P1P2 | Completed | 29 | RCT, Double-blind | Placebo, Brincidofovir |
| NCT00822094 Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | P2 | Completed | 126 | RCT, Open-label | CPX-351, Intensive Salvage Therapy |
| NCT00942305 Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients | Cytomegalovirus Infection | P2 | Completed | 239 | RCT, Double-blind | Brincidofovir, Placebo |
| NCT02565108 A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol | Epilepsy | P2 | Completed | 20 | RCT, Double-blind | GWP42003-P 20 mg/kg/Day Dose, Placebo, Clobazam |
| NCT00361842 Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer | Colorectal Neoplasms | P2 | Completed | 65 | Open-label | CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection |
| NCT01812616 A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients | Cancer | P1P2 | Completed | 21 | RCT, Double-blind | Sativex, Placebo |
| NCT00457951 A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD | Chronic Obstructive Pulmonary Disease | P2 | Terminated | 158 | RCT, Double-blind | Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH |
| NCT02607904 An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy | Epilepsy | P2 | Completed | 30 | Open-label | GWP42003-P |
| NCT00788892 Trial of CPX-351 in Newly Diagnosed Elderly AML Patients | Acute Myeloid Leukemia | P2 | Completed | 126 | RCT, Open-label | CPX-351, Cytarabine, Daunorubicin |
| NCT03436953 A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease | Parkinson's Disease, Tremor | P2 | Withdrawn | — | RCT, Double-blind | CX-8998, Placebo |
| NCT02091206 A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) | Epilepsy, Dravet Syndrome | P2 | Completed | 34 | RCT, Double-blind | GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose |
| NCT02806908 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy | Narcolepsy, Excessive Sleepiness | P2 | Completed | 24 | RCT, Double-blind | JZP-110, Placebo |
| NCT04425655 Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. | Acute Myeloid Leukemia, Adult, AML | P2 | Terminated | 2 | Open-label | Fludarabine, Vyxeos |
| NCT04466891 A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers | HER2-amplified Biliary Tract Cancers | P2 | Completed | 87 | Open-label | ZW25 (Zanidatamab) |
| NCT04195945 CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | Acute Myeloid Leukemia, Myeloid Neoplasm | P2 | Completed | 60 | RCT, Open-label | Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone |
| NCT03406702 CX-8998 for Absence Seizures | Epilepsy | P2 | Completed | 7 | Open-label | CX-8998 |
| NCT04982354 Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1P2 | Withdrawn | — | Open-label | CPX-351, Midostaurin, Busulfan, Melphalan, Fludarabine, CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor |
| NCT03575325 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | Lymphoid Leukemia, Acute Lymphoblastic Leukemia | P2 | Completed | 11 | Open-label | CPX-351 |
| NCT06012929 A Study of ONC201 for Refractory Meningioma | Meningioma, Refractory Meningioma | P2 | Withdrawn | — | Open-label | ONC201 |
| NCT04526288 CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | P2 | Terminated | 1 | RCT, Open-label | Liposome-encapsulated Daunorubicin-Cytarabine |
| NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | P2 | Completed | 74 | Open-label | ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine |
| NCT02525692 Oral ONC201 in Adult Recurrent Glioblastoma | Glioblastoma, Diffuse Midline Glioma | P2 | Terminated | 84 | Open-label | Dordaviprone (ONC201) |
| NCT02257684 A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar) | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | P2 | Terminated | 4 | Open-label | pegcrisantaspase |
| NCT04745026 Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder | Autism Spectrum Disorder | P2 | Completed | 103 | RCT, Double-blind | GWP42003-P, Placebo |
| NCT02419469 Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Leukemia, Precursor-B Acute Lymphoblastic Leukemia | P2 | Terminated | 1 | Open-label | Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine |
| NCT00594945 Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures | Epilepsy | P2 | Completed | 45 | Open-label | Clonazepam |
| NCT06261502 Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome | Fragile X Syndrome | P2 | Not Yet Recruiting | 40 | RCT, Double-blind | CBD Oral Solution, Placebo |
| NCT00931164 Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO) | Alternating Hemiplegia of Childhood | P1P2 | Completed | 6 | Open-label | Sodium Oxybate |
| NCT02863991 Oral ONC201 in Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Terminated | 17 | RCT, Open-label | ONC201, Dexamethasone |
| NCT03295396 ONC201 in Adults With Recurrent H3 K27M-mutant Glioma | Glioma | P2 | Terminated | 73 | Open-label | Dordaviprone (ONC201) |
| NCT06217536 Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | Locally Advanced Soft Tissue Sarcoma | P1P2 | Withdrawn | — | Open-label | Lurbinectedin |
| NCT01812603 A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma | Cancer | P1P2 | Completed | 6 | Open-label | Sativex |
| NCT02365610 A Study of GWP42006 in People With Focal Seizures - Part B | Epilepsy, Focal Seizures | P2 | Completed | 162 | RCT, Double-blind | GWP42006, Placebo Control |
| NCT02564952 An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol | Epilepsy | P2 | Completed | 18 | Open-label | GWP42003-P, Clobazam |
| NCT06261450 Effect of CBD on the Brain | Fragile X Syndrome | P2 | Not Yet Recruiting | 50 | RCT, Double-blind | CBD Oral Solution (eCBD system Target), Placebo |
| NCT05126433 Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor, Metastatic Solid Tumor | P2 | Terminated | 47 | Open-label | Lurbinectedin |
| NCT03849456 Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder | Autism Spectrum Disorder | P2 | Terminated | 1 | Open-label | GWP42006 |
| NCT01241344 Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease | Adenovirus Disease | P2 | Completed | 52 | RCT, Double-blind | Brincidofovir |
| NCT03335267 Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia | Leukemia, Myeloid, Acute | P2 | Completed | 30 | Open-label | CPX-351 |
| NCT01323569 Abuse Potential of Sativex | Evaluation of Abuse Potential of Sativex | P1 | Completed | 58 | RCT, Double-blind | Sativex, Sativex, Sativex, Placebo, Marinol, Marinol |
| NCT00780182 Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers | Healthy | P1 | Completed | 24 | RCT, Open-label | CMX001 |
| NCT02056782 A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1 | Completed | 12 | Open-label | Dociparstat sodium |
| NCT05391724 Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects | Hepatic Impairment | P1 | Completed | 25 | Open-label | CMX001 |
| NCT01551524 Phase I Study of mPEG-R-Crisantaspase Given IV | Hematologic Malignancies | P1 | Completed | 36 | Open-label | mPEG-r-crisantaspase |
| NCT02647190 Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older | Acute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative | P1 | Withdrawn | — | Open-label | Erwinia Chrysanthemi asparaginase |
| NCT04721691 Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES). | Electrical Status Epilepticus of Slow-Wave Sleep | P1 | Completed | 16 | RCT, Double-blind | Epidiolex 100 mg/mL Oral Solution |
| NCT00389428 Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. | Hematologic Neoplasms | P1 | Completed | 48 | Open-label | CPX-351 (Cytarabine:Daunorubicin) Liposome Injection |
| NCT04038437 A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML | Acute Myeloid Leukemia | P1 | Completed | 35 | Open-label | CPX-351, Venetoclax |
| NCT05651152 A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants | Healthy Participants | P1 | Completed | 105 | RCT, Double-blind | JZP441, Placebo |
| NCT01080820 A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers | Healthy | P1 | Completed | 36 | RCT, Double-blind | CMX157, Placebo, Viread |
| NCT02325011 An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience. | Healthy Subjects | P1 | Completed | 14 | RCT, Open-label | Sativex® (Treatment A), Sativex® and fluconazole concomitantly (Treatment B) |
| NCT04530604 Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) | COVID, Sars-CoV2 | P1 | Completed | 13 | Open-label | Defibrotide |
| NCT01323465 Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 | P1 | Completed | 36 | RCT, Open-label | Sativex and rifampicin, Sativex and rifampicin, Sativex and ketoconazole, Sativex and ketoconazole, Sativex and omeprazole, Sativex and omeprazole |
| NCT03878927 CPX-351+GO in Subjects 55 Years Old, or Older, With AML | Acute Myeloid Leukemia | P1 | Terminated | 11 | Open-label | CPX-351, Gemtuzumab Ozogamicin |
| NCT01161641 Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery | Protein Losing Enteropathy | P1 | Terminated | 5 | Open-label | ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h |
| NCT06961266 A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 | Narcolepsy | P1 | Terminated | 6 | RCT, Double-blind | JZP441, Matching Placebo |
| NCT01887301 Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients | Hepatic Impairment | P1 | Completed | 32 | Open-label | Sativex |
| NCT01943682 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | P1 | Completed | 27 | Open-label | CPX-351 |
| NCT05631327 A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor, Metastatic Solid Tumor | P1 | Terminated | 12 | Open-label | JZP341 |
| NCT03416530 ONC201 in Pediatric H3 K27M Gliomas | Diffuse Intrinsic Pontine Glioma, Glioma, Malignant | P1 | Terminated | 134 | Open-label | Dordaviprone (ONC201) |
| NCT05720494 A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants | Healthy Participants | P1 | Completed | 24 | RCT, Double-blind | JZP441, Placebo |
| NCT03904251 CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia | Acute Myelogenous Leukemia | P1 | Terminated | 13 | Open-label | Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine |
| NCT04610658 Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer | P1 | Terminated | 9 | Open-label | Nivolumab, Ipilimumab, Lurbinectedin |
| NCT03555955 A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | Hematologic Malignancy, Acute Myeloid Leukemia | P1 | Completed | 21 | Open-label | CPX-351, CPX-351 |
| NCT02892123 Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | HER2-expressing Cancers | P1 | Completed | 279 | Open-label | ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib, Tucatinib |
| NCT04075747 A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1 | Completed | 57 | Open-label | CPX-351, Venetoclax, Midostaurin, Enasidenib |
| NCT00693602 Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma | Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma | P1 | Completed | 87 | Open-label | Erwinase |
| NCT01918735 A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects | Epilepsy | P1 | Completed | 66 | RCT, Double-blind | Placebo, GWP42006 |
| NCT01322464 Study to Assess Food Effect on Sativex Bioavailability | Food Effect | P1 | Completed | 25 | RCT, Open-label | Sativex, Sativex, Sativex, Sativex |
| NCT00875693 A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) | Acute Myelogenous Leukemia, Myelodysplastic Syndrome | P1 | Completed | 47 | Open-label | CPX-351 |
| NCT01322139 Sativex Thorough QT/QTc Study | Effects of Sativex on ECG | P1 | Completed | 258 | RCT, Double-blind | Placebo spray and oral moxifloxacin placebo, Sativex spray and oral moxifloxacin placebo, Sativex spray and oral moxifloxacin placebo, Placebo spray and moxifloxacin |
| NCT03393611 CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | Myelodysplastic Syndromes, Leukemia, Myeloid, Acute | P1 | Completed | 14 | Open-label | CPX-351, Fludarabine, Melphalan, Rabbit Anti-Human T-Lymphocyte Globulin, Haplo-Cord Stem Cell Transplantation |
| NCT02769780 A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy | Narcolepsy | Completed | 1,500 | — | — | |
| NCT00590915 Erwinase Master Treatment Protocol | Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia | NO_LONGER_AVAILABLE | — | — | Erwinia L-asparaginase | |
| NCT05392374 Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas | Glioma | NO_LONGER_AVAILABLE | — | — | ONC201 | |
| NCT05169307 CPX-351 Real-World Effectiveness and Safety Study | Acute Myeloid Leukemia | Completed | 147 | — | CPX-351 | |
| NCT06143839 VYxeoS Liposomal Italian Observational Study iN the Real Practice | Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Completed | 113 | — | Vyxeos liposomal | |
| NCT04291937 A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA | Small Cell Lung Cancer | APPROVED_FOR_MARKETING | — | — | Lurbinectedin | |
| NCT02596997 Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease | Adenovirus | NO_LONGER_AVAILABLE | — | — | Brincidofovir | |
| NCT05055271 Delphi Consensus Excessive Daytime Sleepiness in OSA | Obstructive Sleep Apnea | Completed | 10 | — | — | |
| NCT04323254 Language of Sleepiness | Sleep, Sleep Disorder | Unknown | 200 | — | — | |
| NCT03134131 Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas | Glioma | NO_LONGER_AVAILABLE | — | — | ONC201 | |
| NCT05826756 Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting | Lung Cancer Patients, Caregivers | Unknown | 1,300 | — | — | |
| NCT03526926 A Post-Marketing Observational Study of VYXEOS™ | Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia | Completed | 52 | — | CPX-351 | |
| NCT04617002 Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas | Glioma, H3 K27M | APPROVED_FOR_MARKETING | — | — | ONC201 (dordaviprone) | |
| NCT04894591 To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) | Extensive-stage Small-cell Lung Cancer | Completed | 272 | — | Zepzelca | |
| NCT02660255 Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy | Epilepsy | APPROVED_FOR_MARKETING | — | — | Cannabidiol | |
| NCT04803786 A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy | Narcolepsy | Completed | 110 | — | Transition from Xyrem to Xywav | |
| NCT03032016 European VOD Registry | Hepatic Veno-Occlusive Disease | Completed | 176 | — | — | |
| NCT02073474 An Observational Post-Marketing Safety Registry of Sativex® | Multiple Sclerosis, Diabetes | Completed | 978 | — | Sativex® | |
| NCT04578444 An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer | HER2-Positive Advanced Biliary Tract Cancer | NO_LONGER_AVAILABLE | — | — | Zanidatamab | |
| NCT02167685 The Chimerix CMX001 Registry | Outcomes, Survival Rates | Terminated | 550 | — | CMX001 | |
| NCT01843634 Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia | Acute Myeloid Leukemia | Early P1 | Completed | 10 | Open-label | ODSH |
| NCT04285788 Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients | Adenovirus Infections, Human | Completed | 216 | — | — | |
| NCT01888120 Patient Registry of Intrathecal Ziconotide Management(PRIZM) | Patients With Severe Chronic Pain | Completed | 93 | — | Ziconotide | |
| NCT02533115 EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML | Secondary AML | APPROVED_FOR_MARKETING | — | — | CPX-351 | |
| NCT04943952 JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | APPROVED_FOR_MARKETING | — | — | Asparaginase Erwinia Chrysanthemi (recombinant) | |
| NCT04176042 Community-Level Daytime Sleepiness: Social-Environmental Determinants, Consequences, and Impact of Sleep Apnea | Daytime Sleepiness | N/A | Completed | 28 | RCT, Single-blind | — |
| NCT02420080 A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304 | Adenovirus | Terminated | 100 | — | Brincidofovir |